Sarepta Therapeutics Boston Consulting Group Matrix
Actionable Strategy Starts Here
Sarepta Therapeutics' product portfolio is a complex web of innovation and market potential. Understanding where each therapy sits within the BCG Matrix—whether a promising Star, a stable Cash Cow, a resource-draining Dog, or a speculative Question Mark—is crucial for informed investment.
This preview offers a glimpse into Sarepta's strategic positioning, but the full BCG Matrix report unlocks the complete picture. Gain detailed quadrant placements, data-driven recommendations, and a clear roadmap to optimize your capital allocation and product development strategies.
Don't miss out on the actionable insights that can shape your investment decisions. Purchase the full Sarepta Therapeutics BCG Matrix today and transform your understanding of their market presence and future growth opportunities.
Stars
Elevidys (Delandistrogene Moxeparvovec) - Ambulatory Patients
Elevidys, Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD), is a clear star in the BCG matrix, especially for ambulatory patients. The therapy achieved significant sales, reaching $384.2 million in Q4 2024 and $375.0 million in Q1 2025, underscoring its robust market performance.
The FDA's expanded approval in June 2024, covering all individuals with DMD aged 4 and older, including traditional approval for ambulatory patients who make up about 70% of the DMD population, solidifies Elevidys' position. This broad label, coupled with its successful launch, points to a substantial market share within the expanding gene therapy sector for rare diseases.
Despite facing temporary setbacks like safety concerns and shipment pauses, the FDA's reauthorization of shipments for ambulatory patients reaffirms Elevidys' strong market standing and its critical role in treating this patient population.
DMD Gene Therapy Platform
Sarepta Therapeutics' gene therapy platform, especially its AAVrh74 technology, is a significant star in the BCG Matrix. This platform is the foundation for Elevidys, a treatment for Duchenne muscular dystrophy (DMD), and other promising pipeline candidates, designed to accelerate drug development.
The company was recognized with one of the FDA's initial platform technology designations in June 2024, a move aimed at expediting the creation and approval of new therapies. Although this designation was later rescinded due to a safety concern, the core technology's promise for treating DMD and other muscle-wasting diseases remains robust.
Early-Stage Gene Therapy Pipeline (e.g., LGMD programs)
Sarepta Therapeutics is actively developing a substantial gene therapy pipeline, featuring over 40 distinct programs. A significant portion of these efforts are directed towards rare genetic disorders, including multiple types of Limb-Girdle Muscular Dystrophies (LGMDs). This focus on unmet medical needs in high-growth rare disease markets positions these early-stage gene therapy candidates as potential future stars.
For instance, Sarepta's program targeting LGMD2E/R4, known as SRP-9003, is progressing through clinical development. The company has indicated that a Biologics License Application (BLA) submission for this therapy is anticipated in 2025. Successful clinical outcomes and subsequent regulatory approvals for these LGMD programs could lead to significant market penetration and revenue generation.
Strategic Partnerships (e.g., Roche for Elevidys ex-US)
Sarepta's collaboration with Roche for the ex-US commercialization of Elevidys is a prime example of a strategic star. This partnership is crucial for expanding Elevidys' global footprint.
Roche is managing the European Medicines Agency (EMA) review, with a potential approval anticipated in 2025. This collaboration is key to unlocking significant international market growth for Elevidys, a therapy targeting Duchenne muscular dystrophy.
These strategic alliances are vital for Sarepta, allowing them to leverage Roche's established global infrastructure and regulatory expertise. This approach not only broadens market access but also accelerates the availability of their innovative therapies in new territories, reinforcing Elevidys' position as a high-growth asset.
- Strategic Star: Sarepta's partnership with Roche for ex-US Elevidys commercialization.
- Market Expansion: Roche's role in EMA review, with 2025 approval expected, signifies growing international potential.
- Leveraging Expertise: The collaboration enhances market reach and utilizes global expertise for Sarepta's lead asset.
RNA-Targeted Approaches (e.g., siRNA programs)
Sarepta Therapeutics is strategically expanding its pipeline by acquiring a diverse range of RNA-targeted therapies, including siRNA programs. These initiatives aim to tap into new therapeutic markets, moving beyond their established focus on Duchenne muscular dystrophy (DMD).
Several of these siRNA programs are anticipated to launch between 2028 and 2029, with projections indicating significant market potential, potentially reaching blockbuster status. For instance, SRP-1001 targets facioscapulohumeral muscular dystrophy type 1 (FSHD1), and SRP-1003 is being developed for myotonic dystrophy type 1 (DM1).
- Portfolio Diversification: Sarepta is actively broadening its therapeutic reach through in-licensing siRNA programs.
- Future Growth Potential: Programs like SRP-1001 (FSHD1) and SRP-1003 (DM1) are positioned as potential blockbuster drugs, with market entry expected in 2028-2029.
- Addressing Unmet Needs: These early-stage RNA-targeted approaches target significant unmet medical needs in new disease areas.
- Star Potential: Their high growth potential and ability to address critical patient populations classify them as future stars within Sarepta's portfolio.
Sarepta's Stellar Performance: Elevidys and Beyond
Elevidys, Sarepta's gene therapy for Duchenne muscular dystrophy (DMD), is a standout star, achieving $384.2 million in Q4 2024 and $375.0 million in Q1 2025 sales. The expanded FDA approval in June 2024 for all individuals aged 4 and older, including the 70% ambulatory patient population, solidifies its market dominance and growth trajectory within the rare disease gene therapy sector.
Sarepta's AAVrh74 gene therapy platform is a foundational star, underpinning Elevidys and a robust pipeline. Despite a temporary rescission of a platform technology designation in June 2024 due to a safety concern, the underlying technology's promise for treating DMD and other muscle disorders remains strong, driving future development.
The company's strategic collaboration with Roche for ex-US Elevidys commercialization represents a significant strategic star. With a potential EMA approval expected in 2025, this partnership is crucial for expanding Elevidys' global reach and leveraging Roche's established infrastructure to accelerate market access.
Sarepta's diversification into RNA-targeted therapies, including siRNA programs like SRP-1001 (FSHD1) and SRP-1003 (DM1), positions them as future stars. These programs, with anticipated launches between 2028-2029 and potential blockbuster status, address significant unmet needs in new therapeutic areas.
| Product/Platform | BCG Category | Key Metrics/Developments | Market Potential |
| Elevidys (DMD Gene Therapy) | Star | $384.2M Q4 2024 Sales, $375.0M Q1 2025 Sales; Expanded FDA Approval (June 2024) | High growth, dominant market share in DMD gene therapy |
| AAVrh74 Gene Therapy Platform | Star | Foundation for Elevidys and pipeline; Robust development for rare muscle disorders | Enables multiple high-potential therapies |
| Roche Collaboration (Ex-US Elevidys) | Strategic Star | Potential EMA Approval (2025); Leverages global infrastructure | Expands global market access and revenue |
| RNA-Targeted Therapies (e.g., siRNA) | Potential Star | SRP-1001 (FSHD1), SRP-1003 (DM1); Anticipated launch 2028-2029 | Potential blockbuster status, addresses new unmet needs |
What is included in the product
Detailed Word Document
Sarepta Therapeutics' BCG Matrix analyzes its gene therapy portfolio, categorizing products by market growth and share.
This framework guides strategic decisions on investing in promising Stars, maintaining Cash Cows, developing Question Marks, and divesting Dogs.
Customizable Excel Spreadsheet
Sarepta's BCG Matrix offers a clear visualization of its pipeline, easing the pain of strategic resource allocation.
This matrix provides a focused view, simplifying complex portfolio decisions for leadership.
Cash Cows
Exondys 51 (Eteplirsen)
Exondys 51, an established phosphorodiamidate morpholino oligomer (PMO) therapy for Duchenne Muscular Dystrophy (DMD), continues to be a significant revenue driver for Sarepta Therapeutics. This therapy contributed to the PMO franchise's impressive $236.5 million in Q1 2025 and $248.8 million in Q3 2024, highlighting its role as a cash cow.
Despite the emergence of new gene therapies in the evolving DMD landscape, Exondys 51 maintains a solid market share among its amenable patient population. Its consistent sales performance, coupled with relatively contained promotional expenses, solidifies its position as a reliable cash generator for Sarepta.
Vyondys 53 (Golodirsen)
Vyondys 53, also known as golodirsen, is a significant product for Sarepta Therapeutics, specifically targeting Duchenne muscular dystrophy (DMD) patients who can benefit from exon 53 skipping. This drug, along with Exondys 51 and Amondys 45, constitutes Sarepta's exon-skipping platform, a consistent revenue generator for the company.
With its established market presence and stable sales within a more mature segment of the DMD treatment landscape, Vyondys 53 functions as a cash cow. It reliably generates consistent cash flow, which is crucial for Sarepta's ongoing research and development efforts in other areas.
Amondys 45 (Casimersen)
Amondys 45 (casimersen) plays a crucial role as a Cash Cow within Sarepta Therapeutics' product portfolio, contributing significantly to the company's financial stability. This therapy, designed for Duchenne Muscular Dystrophy (DMD) patients with specific exon 45 skipping mutations, is the third peptide-morpholino oligonucleotide (PMO) therapy offered by Sarepta. Its established presence and effectiveness have solidified its market share within its specialized segment of the DMD market.
The steady revenue generated by Amondys 45 is a key characteristic of a Cash Cow. In the first quarter of 2025, Sarepta's entire PMO franchise, which includes Amondys 45, collectively brought in $236.5 million. This consistent financial performance indicates a mature product with a strong market position, requiring minimal additional investment for growth or market penetration.
PMO Franchise (Combined)
The combined PMO franchise, which includes Exondys 51, Vyondys 53, and Amondys 45, serves as a substantial cash cow for Sarepta Therapeutics. This segment of their business has shown robust and consistent financial performance.
- The PMO franchise achieved $236.5 million in revenue during the first quarter of 2025.
- In the third quarter of 2024, the franchise reported $248.8 million in sales.
- These products have demonstrated resilience, with minimal near-term cannibalization observed despite the introduction of new gene therapies.
- This stable revenue stream is crucial for Sarepta, providing essential funding for ongoing research and development efforts, as well as other strategic corporate ventures.
Manufacturing Capabilities
Sarepta Therapeutics' established manufacturing capabilities for its approved therapies, especially its Duchenne muscular dystrophy (DMD) gene therapy products, function as a significant cash cow. These efficient processes for existing treatments translate into healthy profit margins and ensure a consistent supply chain. For instance, in Q1 2024, Sarepta reported total revenue of $279.5 million, a substantial portion of which is driven by its commercial products like Exondys 51, Amondys 45, and Translarna, underscoring the financial strength derived from these mature offerings.
The company's strategic investment in its manufacturing infrastructure, notably its Genetic Therapies Center of Excellence, is a key factor supporting these cash cow operations. This facility not only meets current product demands but also provides a robust foundation for scaling future pipeline assets. This commitment to manufacturing excellence ensures operational efficiency and cost-effectiveness, further solidifying the cash-generating potential of its approved gene therapies.
- Established Product Revenue: Sarepta's commercial portfolio, including Exondys 51 and Amondys 45, continues to be a primary revenue driver, generating significant cash flow.
- Manufacturing Efficiency: Optimized production processes for its approved therapies contribute to strong profit margins and reliable product availability.
- Infrastructure Investment: The Genetic Therapies Center of Excellence represents a strategic investment that supports current cash cow products and future growth.
- Market Position: Sarepta holds a leading position in the DMD treatment market, providing a stable demand base for its established therapies.
DMD Therapies: The Financial Backbone
Sarepta's established Duchenne Muscular Dystrophy (DMD) therapies, particularly the phosphorodiamidate morpholino oligomer (PMO) franchise including Exondys 51, Vyondys 53, and Amondys 45, are prime examples of cash cows. These products benefit from a strong market position and consistent demand within a defined patient population.
The PMO franchise demonstrated robust financial performance, generating $236.5 million in Q1 2025 and $248.8 million in Q3 2024. This sustained revenue stream, despite the emergence of newer treatments, highlights their stability and low need for reinvestment.
These mature therapies are crucial for funding Sarepta's ongoing research and development, including its pipeline of gene therapies. Their reliable cash generation underpins the company's ability to invest in future innovation and maintain its leadership in the rare disease space.
| Product | Therapeutic Area | 2024 Q3 Revenue (Millions) | 2025 Q1 Revenue (Millions) | BCG Matrix Category |
|---|---|---|---|---|
| Exondys 51 | DMD | N/A (part of franchise) | N/A (part of franchise) | Cash Cow |
| Vyondys 53 | DMD | N/A (part of franchise) | N/A (part of franchise) | Cash Cow |
| Amondys 45 | DMD | N/A (part of franchise) | N/A (part of franchise) | Cash Cow |
| PMO Franchise (Combined) | DMD | $248.8 | $236.5 | Cash Cow |
Preview = Final Product
Sarepta Therapeutics BCG Matrix
The Sarepta Therapeutics BCG Matrix preview you are viewing is the identical, fully formatted document you will receive immediately after purchase. This comprehensive analysis, meticulously prepared, will be delivered to you without any watermarks or sample content, ensuring you get the complete strategic tool you need.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Actionable Strategy Starts Here
Sarepta Therapeutics' product portfolio is a complex web of innovation and market potential. Understanding where each therapy sits within the BCG Matrix—whether a promising Star, a stable Cash Cow, a resource-draining Dog, or a speculative Question Mark—is crucial for informed investment.
This preview offers a glimpse into Sarepta's strategic positioning, but the full BCG Matrix report unlocks the complete picture. Gain detailed quadrant placements, data-driven recommendations, and a clear roadmap to optimize your capital allocation and product development strategies.
Don't miss out on the actionable insights that can shape your investment decisions. Purchase the full Sarepta Therapeutics BCG Matrix today and transform your understanding of their market presence and future growth opportunities.
Stars
Elevidys (Delandistrogene Moxeparvovec) - Ambulatory Patients
Elevidys, Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD), is a clear star in the BCG matrix, especially for ambulatory patients. The therapy achieved significant sales, reaching $384.2 million in Q4 2024 and $375.0 million in Q1 2025, underscoring its robust market performance.
The FDA's expanded approval in June 2024, covering all individuals with DMD aged 4 and older, including traditional approval for ambulatory patients who make up about 70% of the DMD population, solidifies Elevidys' position. This broad label, coupled with its successful launch, points to a substantial market share within the expanding gene therapy sector for rare diseases.
Despite facing temporary setbacks like safety concerns and shipment pauses, the FDA's reauthorization of shipments for ambulatory patients reaffirms Elevidys' strong market standing and its critical role in treating this patient population.
DMD Gene Therapy Platform
Sarepta Therapeutics' gene therapy platform, especially its AAVrh74 technology, is a significant star in the BCG Matrix. This platform is the foundation for Elevidys, a treatment for Duchenne muscular dystrophy (DMD), and other promising pipeline candidates, designed to accelerate drug development.
The company was recognized with one of the FDA's initial platform technology designations in June 2024, a move aimed at expediting the creation and approval of new therapies. Although this designation was later rescinded due to a safety concern, the core technology's promise for treating DMD and other muscle-wasting diseases remains robust.
Early-Stage Gene Therapy Pipeline (e.g., LGMD programs)
Sarepta Therapeutics is actively developing a substantial gene therapy pipeline, featuring over 40 distinct programs. A significant portion of these efforts are directed towards rare genetic disorders, including multiple types of Limb-Girdle Muscular Dystrophies (LGMDs). This focus on unmet medical needs in high-growth rare disease markets positions these early-stage gene therapy candidates as potential future stars.
For instance, Sarepta's program targeting LGMD2E/R4, known as SRP-9003, is progressing through clinical development. The company has indicated that a Biologics License Application (BLA) submission for this therapy is anticipated in 2025. Successful clinical outcomes and subsequent regulatory approvals for these LGMD programs could lead to significant market penetration and revenue generation.
Strategic Partnerships (e.g., Roche for Elevidys ex-US)
Sarepta's collaboration with Roche for the ex-US commercialization of Elevidys is a prime example of a strategic star. This partnership is crucial for expanding Elevidys' global footprint.
Roche is managing the European Medicines Agency (EMA) review, with a potential approval anticipated in 2025. This collaboration is key to unlocking significant international market growth for Elevidys, a therapy targeting Duchenne muscular dystrophy.
These strategic alliances are vital for Sarepta, allowing them to leverage Roche's established global infrastructure and regulatory expertise. This approach not only broadens market access but also accelerates the availability of their innovative therapies in new territories, reinforcing Elevidys' position as a high-growth asset.
- Strategic Star: Sarepta's partnership with Roche for ex-US Elevidys commercialization.
- Market Expansion: Roche's role in EMA review, with 2025 approval expected, signifies growing international potential.
- Leveraging Expertise: The collaboration enhances market reach and utilizes global expertise for Sarepta's lead asset.
RNA-Targeted Approaches (e.g., siRNA programs)
Sarepta Therapeutics is strategically expanding its pipeline by acquiring a diverse range of RNA-targeted therapies, including siRNA programs. These initiatives aim to tap into new therapeutic markets, moving beyond their established focus on Duchenne muscular dystrophy (DMD).
Several of these siRNA programs are anticipated to launch between 2028 and 2029, with projections indicating significant market potential, potentially reaching blockbuster status. For instance, SRP-1001 targets facioscapulohumeral muscular dystrophy type 1 (FSHD1), and SRP-1003 is being developed for myotonic dystrophy type 1 (DM1).
- Portfolio Diversification: Sarepta is actively broadening its therapeutic reach through in-licensing siRNA programs.
- Future Growth Potential: Programs like SRP-1001 (FSHD1) and SRP-1003 (DM1) are positioned as potential blockbuster drugs, with market entry expected in 2028-2029.
- Addressing Unmet Needs: These early-stage RNA-targeted approaches target significant unmet medical needs in new disease areas.
- Star Potential: Their high growth potential and ability to address critical patient populations classify them as future stars within Sarepta's portfolio.
Sarepta's Stellar Performance: Elevidys and Beyond
Elevidys, Sarepta's gene therapy for Duchenne muscular dystrophy (DMD), is a standout star, achieving $384.2 million in Q4 2024 and $375.0 million in Q1 2025 sales. The expanded FDA approval in June 2024 for all individuals aged 4 and older, including the 70% ambulatory patient population, solidifies its market dominance and growth trajectory within the rare disease gene therapy sector.
Sarepta's AAVrh74 gene therapy platform is a foundational star, underpinning Elevidys and a robust pipeline. Despite a temporary rescission of a platform technology designation in June 2024 due to a safety concern, the underlying technology's promise for treating DMD and other muscle disorders remains strong, driving future development.
The company's strategic collaboration with Roche for ex-US Elevidys commercialization represents a significant strategic star. With a potential EMA approval expected in 2025, this partnership is crucial for expanding Elevidys' global reach and leveraging Roche's established infrastructure to accelerate market access.
Sarepta's diversification into RNA-targeted therapies, including siRNA programs like SRP-1001 (FSHD1) and SRP-1003 (DM1), positions them as future stars. These programs, with anticipated launches between 2028-2029 and potential blockbuster status, address significant unmet needs in new therapeutic areas.
| Product/Platform | BCG Category | Key Metrics/Developments | Market Potential |
| Elevidys (DMD Gene Therapy) | Star | $384.2M Q4 2024 Sales, $375.0M Q1 2025 Sales; Expanded FDA Approval (June 2024) | High growth, dominant market share in DMD gene therapy |
| AAVrh74 Gene Therapy Platform | Star | Foundation for Elevidys and pipeline; Robust development for rare muscle disorders | Enables multiple high-potential therapies |
| Roche Collaboration (Ex-US Elevidys) | Strategic Star | Potential EMA Approval (2025); Leverages global infrastructure | Expands global market access and revenue |
| RNA-Targeted Therapies (e.g., siRNA) | Potential Star | SRP-1001 (FSHD1), SRP-1003 (DM1); Anticipated launch 2028-2029 | Potential blockbuster status, addresses new unmet needs |
What is included in the product
Detailed Word Document
Sarepta Therapeutics' BCG Matrix analyzes its gene therapy portfolio, categorizing products by market growth and share.
This framework guides strategic decisions on investing in promising Stars, maintaining Cash Cows, developing Question Marks, and divesting Dogs.
Customizable Excel Spreadsheet
Sarepta's BCG Matrix offers a clear visualization of its pipeline, easing the pain of strategic resource allocation.
This matrix provides a focused view, simplifying complex portfolio decisions for leadership.
Cash Cows
Exondys 51 (Eteplirsen)
Exondys 51, an established phosphorodiamidate morpholino oligomer (PMO) therapy for Duchenne Muscular Dystrophy (DMD), continues to be a significant revenue driver for Sarepta Therapeutics. This therapy contributed to the PMO franchise's impressive $236.5 million in Q1 2025 and $248.8 million in Q3 2024, highlighting its role as a cash cow.
Despite the emergence of new gene therapies in the evolving DMD landscape, Exondys 51 maintains a solid market share among its amenable patient population. Its consistent sales performance, coupled with relatively contained promotional expenses, solidifies its position as a reliable cash generator for Sarepta.
Vyondys 53 (Golodirsen)
Vyondys 53, also known as golodirsen, is a significant product for Sarepta Therapeutics, specifically targeting Duchenne muscular dystrophy (DMD) patients who can benefit from exon 53 skipping. This drug, along with Exondys 51 and Amondys 45, constitutes Sarepta's exon-skipping platform, a consistent revenue generator for the company.
With its established market presence and stable sales within a more mature segment of the DMD treatment landscape, Vyondys 53 functions as a cash cow. It reliably generates consistent cash flow, which is crucial for Sarepta's ongoing research and development efforts in other areas.
Amondys 45 (Casimersen)
Amondys 45 (casimersen) plays a crucial role as a Cash Cow within Sarepta Therapeutics' product portfolio, contributing significantly to the company's financial stability. This therapy, designed for Duchenne Muscular Dystrophy (DMD) patients with specific exon 45 skipping mutations, is the third peptide-morpholino oligonucleotide (PMO) therapy offered by Sarepta. Its established presence and effectiveness have solidified its market share within its specialized segment of the DMD market.
The steady revenue generated by Amondys 45 is a key characteristic of a Cash Cow. In the first quarter of 2025, Sarepta's entire PMO franchise, which includes Amondys 45, collectively brought in $236.5 million. This consistent financial performance indicates a mature product with a strong market position, requiring minimal additional investment for growth or market penetration.
PMO Franchise (Combined)
The combined PMO franchise, which includes Exondys 51, Vyondys 53, and Amondys 45, serves as a substantial cash cow for Sarepta Therapeutics. This segment of their business has shown robust and consistent financial performance.
- The PMO franchise achieved $236.5 million in revenue during the first quarter of 2025.
- In the third quarter of 2024, the franchise reported $248.8 million in sales.
- These products have demonstrated resilience, with minimal near-term cannibalization observed despite the introduction of new gene therapies.
- This stable revenue stream is crucial for Sarepta, providing essential funding for ongoing research and development efforts, as well as other strategic corporate ventures.
Manufacturing Capabilities
Sarepta Therapeutics' established manufacturing capabilities for its approved therapies, especially its Duchenne muscular dystrophy (DMD) gene therapy products, function as a significant cash cow. These efficient processes for existing treatments translate into healthy profit margins and ensure a consistent supply chain. For instance, in Q1 2024, Sarepta reported total revenue of $279.5 million, a substantial portion of which is driven by its commercial products like Exondys 51, Amondys 45, and Translarna, underscoring the financial strength derived from these mature offerings.
The company's strategic investment in its manufacturing infrastructure, notably its Genetic Therapies Center of Excellence, is a key factor supporting these cash cow operations. This facility not only meets current product demands but also provides a robust foundation for scaling future pipeline assets. This commitment to manufacturing excellence ensures operational efficiency and cost-effectiveness, further solidifying the cash-generating potential of its approved gene therapies.
- Established Product Revenue: Sarepta's commercial portfolio, including Exondys 51 and Amondys 45, continues to be a primary revenue driver, generating significant cash flow.
- Manufacturing Efficiency: Optimized production processes for its approved therapies contribute to strong profit margins and reliable product availability.
- Infrastructure Investment: The Genetic Therapies Center of Excellence represents a strategic investment that supports current cash cow products and future growth.
- Market Position: Sarepta holds a leading position in the DMD treatment market, providing a stable demand base for its established therapies.
DMD Therapies: The Financial Backbone
Sarepta's established Duchenne Muscular Dystrophy (DMD) therapies, particularly the phosphorodiamidate morpholino oligomer (PMO) franchise including Exondys 51, Vyondys 53, and Amondys 45, are prime examples of cash cows. These products benefit from a strong market position and consistent demand within a defined patient population.
The PMO franchise demonstrated robust financial performance, generating $236.5 million in Q1 2025 and $248.8 million in Q3 2024. This sustained revenue stream, despite the emergence of newer treatments, highlights their stability and low need for reinvestment.
These mature therapies are crucial for funding Sarepta's ongoing research and development, including its pipeline of gene therapies. Their reliable cash generation underpins the company's ability to invest in future innovation and maintain its leadership in the rare disease space.
| Product | Therapeutic Area | 2024 Q3 Revenue (Millions) | 2025 Q1 Revenue (Millions) | BCG Matrix Category |
|---|---|---|---|---|
| Exondys 51 | DMD | N/A (part of franchise) | N/A (part of franchise) | Cash Cow |
| Vyondys 53 | DMD | N/A (part of franchise) | N/A (part of franchise) | Cash Cow |
| Amondys 45 | DMD | N/A (part of franchise) | N/A (part of franchise) | Cash Cow |
| PMO Franchise (Combined) | DMD | $248.8 | $236.5 | Cash Cow |
Preview = Final Product
Sarepta Therapeutics BCG Matrix
The Sarepta Therapeutics BCG Matrix preview you are viewing is the identical, fully formatted document you will receive immediately after purchase. This comprehensive analysis, meticulously prepared, will be delivered to you without any watermarks or sample content, ensuring you get the complete strategic tool you need.
